Abstract:SARS-CoV-2 is the novel coronavirus causing the COVID-19 pandemic. To enter human cells, the receptor-binding domain (RBD) of the S1 subunit of SARS-CoV-2 (SARS-CoV-2-RBD) initially binds to the peptidase domain of angiotensin-converting enzyme 2 receptor (ACE2-PD). Using peptides to inhibit SARS-CoV-2-RBD binding to ACE2 is a potential therapeutic solution for COVID-19. A previous study identified a 23-mer peptide (SBP1) that bound to SARS-CoV-2-RBD with comparable KD to ACE2. We employed computational protein design and molecular dynamics (MD) to design SARS-CoV-2-RBD 25-mer peptide binders (SPB25) with better predicted binding affinity than SBP1. Using residues 21–45 of the α1 helix of ACE2-PD as the template, our strategy is employing Rosetta to enhance SPB25 binding affinity to SARS-CoV-2-RBD and avoid disrupting existing favorable interactions by using residues that have not been reported to form favorable interactions with SARS-CoV-2-RBD as designed positions. Designed peptides with better predicted binding affinities, by Rosetta, than SPB25 were subjected to MD validation. The MD results show that five designed peptides (SPB25F8N, SPB25F8R, SPB25L25R, SPB25F8N/L25R, and SPB25F8R/L25R) have better predicted binding affinities, by the MM-GBSA method, than SPB25 and SBP1. This study developed an approach to design SARS-CoV-2-RBD peptide binders, and these peptides may be promising candidates as potential SARS-CoV-2 inhibitors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jpcb.0c07890?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jpcb.0c07890</a>.rmsd plots of ACE2, SBP1, SPB25, and designed peptides in complex with SARS-CoV-2-RBD; rmsd plots of ACE2, SBP1, SPB25, and designed peptides in water; binding free energies of ACE2, SBP1, SPB25, and all designed peptides to SARS-CoV-2-RBD, as calculated with Rosetta and the MM-GBSA method; and hydrogen bond occupations of ACE2, SBP1, SPB25, and designed peptide binding to SARS-CoV-2-RBD (<a class="ext-link" href="/doi/suppl/10.1021/acs.jpcb.0c07890/suppl_file/jp0c07890_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Computational Design of 25-mer Peptide Binders of SARS-CoV-2

Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Computational Analysis on the ACE2-derived Peptides for Neutralizing the ACE2 Binding to the Spike Protein of SARS-CoV-2

Design of protein-binding peptides with controlled binding affinity: the case of SARS-CoV-2 receptor binding domain and angiotensin-converting enzyme 2 derived peptides

A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor

De novo design of covalent bonding peptides for target protein

Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2

A Rationally Designed Synthetic Antiviral Peptide Binder Targeting the Receptor-Binding Domain of SARS-CoV-2

Computational Design and Modeling of Nanobodies Toward SARS‐CoV‐2 Receptor Binding Domain

Computational Discovery of SARS-CoV-2 Main Protease Inhibitors Via a Virtual Screening, Molecular Docking, Molecular Dynamics and MM/PBSA Calculations-Driven Approach

Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression

Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein

Peptide S4 is an entry inhibitor of SARS-CoV-2 infection

Dendrimer-Peptide Conjugates for Effective Blockade of the Interactions Between SARS-CoV-2 Spike Protein and Human ACE2 Receptor

Molecular Docking and Dynamics Studies to Explore Effective Inhibitory Peptides Against the Spike Receptor Binding Domain of SARS-CoV-2

Peptide inhibitors derived from the nsp7 and nsp8 cofactors of nsp12 targeting different substrate binding sites of nsp12 of the SARS-CoV-2

Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein